Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in an upcoming industry event. John Celebi, President and CEO, will be a panelist in the New Radiotherapy and Targeted Therapy Approaches discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for Monday, April 7 at 2:00 p.m. ET.
Sensei Biotherapeutics (Nasdaq: SNSE), una società biotecnologica in fase clinica specializzata in terapie oncologiche di nuova generazione, ha annunciato la sua partecipazione a un prossimo evento del settore. John Celebi, Presidente e CEO, sarà un relatore nel dibattito su Nuove Approcci alla Radioterapia e alla Terapia Mirata durante la Conferenza Virtuale Canaccord Genuity Horizons in Oncology. Il panel è programmato per lunedì 7 aprile alle 14:00 ET.
Sensei Biotherapeutics (Nasdaq: SNSE), una empresa biotecnológica en etapa clínica especializada en terapias oncológicas de nueva generación, ha anunciado su participación en un próximo evento de la industria. John Celebi, Presidente y CEO, será panelista en la discusión sobre Nuevos Enfoques en Radioterapia y Terapia Dirigida en la Conferencia Virtual Canaccord Genuity Horizons in Oncology. El panel está programado para el lunes 7 de abril a las 2:00 p.m. ET.
센세이 생명공학 (Nasdaq: SNSE), 차세대 암 치료제를 전문으로 하는 임상 단계의 생명공학 회사가 다가오는 산업 행사에 참여한다고 발표했습니다. 존 셀레비, 사장 겸 CEO가 캐너코드 제뉴이티 호라이즌스 인 온콜로지 가상 회의에서 새로운 방사선 치료 및 표적 치료 접근법에 대한 패널리스트로 참여할 예정입니다. 패널은 4월 7일 월요일 오후 2시에 예정되어 있습니다. ET.
Sensei Biotherapeutics (Nasdaq: SNSE), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies anticancéreuses de nouvelle génération, a annoncé sa participation à un prochain événement de l'industrie. John Celebi, Président et CEO, sera panéliste lors de la discussion sur les Nouvelles Approches en Radiothérapie et Thérapie Ciblée lors de la Conférence Virtuelle Canaccord Genuity Horizons in Oncology. Le panel est prévu pour le lundi 7 avril à 14h00 ET.
Sensei Biotherapeutics (Nasdaq: SNSE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien der nächsten Generation gegen Krebs spezialisiert hat, hat seine Teilnahme an einer bevorstehenden Branchenveranstaltung bekannt gegeben. John Celebi, Präsident und CEO, wird als Podiumsteilnehmer an der Diskussion über Neue Ansätze in der Strahlentherapie und gezielten Therapie auf der Canaccord Genuity Horizons in Oncology Virtuellen Konferenz teilnehmen. Das Panel ist für Montag, den 7. April um 14:00 Uhr ET angesetzt.
- None.
- None.
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET.
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com
Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
When is Sensei Biotherapeutics (SNSE) presenting at the Canaccord Genuity Oncology Conference?
What panel will SNSE CEO John Celebi participate in at the Canaccord conference?
What is Sensei Biotherapeutics' (SNSE) current development focus?
What is Sensei Biotherapeutics' (SNSE) current stage of development?
